Noom and Zepbound: Editorial Look at the Telehealth Program

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

You are reading a PlexusDx Education Hub article on GLP-1 and dual-agonist therapies, the programs that make them accessible, and the genetic details that underpin every metabolic choice. Browse all Peptides & GLP-1 education

What follows is an independent editorial review. PlexusDx has no commercial relationship with Noom or its parent company, and no affiliate links or payments are involved in this article.

Searches that combine Noom with Zepbound generally come from readers weighing a subscription program against a branded dual-agonist medication. This review explains what Zepbound is, how a request like it moves through Noom's telehealth model, what influences the cost, the trial record behind the compound, and the pathway genetics a telehealth intake never surfaces. Even-handed framing, current to April 2026, and not a buying recommendation.

What Zepbound is and how Noom's program relates to it

Zepbound is a branded tirzepatide product from Eli Lilly, a GIP/GLP-1 dual agonist approved for weight management and, more recently, obstructive sleep apnea. Noom (Noom, Inc.) is structured as an app-based subscription with a medication add-on, meaning a dual-agonist request typically runs through a virtual clinical evaluation, a prescription directed either to a retail pharmacy for the branded product or to a 503A compounding pharmacy for a compounded tirzepatide preparation, and continued follow-up. Noom keeps its current program details on its official website.

Routing a Zepbound-style request through telehealth

When a patient asks about a branded dual agonist, telehealth programs usually follow a set path: an intake covering weight, medical history and medications; a licensed clinician's review that must confirm eligibility before a prescription exists; routing to a retail pharmacy for the brand or a licensed compounding pharmacy for a compounded version; and periodic virtual visits to guide titration and address side effects. The clinician type, pharmacy partner and subscription model are where individual programs diverge.

Cost factors when Zepbound is the target

Because Zepbound is a branded product, the dispensing route matters a great deal. Noom lists its own pricing, which changes over time, and the monthly total depends on the compound, the subscription tier, and whether the pharmacy supplies the branded medication or a compounded alternative. Across the telehealth GLP-1 market as of April 2026, monthly figures commonly range from roughly $200 to $700+, with wide variance. Confirm the live number at Noom's official website before committing.

SURMOUNT and SURMOUNT-OSA: what the tirzepatide trials showed

The evidence behind tirzepatide sits within the broader compound class — GLP-1 receptor agonists such as semaglutide, liraglutide and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide itself. Tirzepatide's weight-management data come from the SURMOUNT program (The New England Journal of Medicine, 2022), and its obstructive sleep apnea data from SURMOUNT-OSA (NEJM 2024); the semaglutide STEP trials (NEJM 2021) sit alongside as the single-agonist comparison. Populations and endpoints differ across studies, and individual outcomes vary.

The genetic context every Zepbound pathway skips

A branded prescription still tells a clinician nothing about the genetic ground a dual agonist works on. GLP1R, the GLP-1 receptor gene these compounds target, is joined by FTO (the fat-mass and obesity-associated gene), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor tied to glucose homeostasis and GLP-1 secretion). These markers are pathway-level. They do not predict how Zepbound or any compound will perform, yet they describe the biology being prescribed into — detail a telehealth form never records.

PlexusDx delivers semaglutide and tirzepatide through its Weight Management Protocols, offered as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The difference is where it starts: before a dual-agonist protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including FTO, MC4R and TCF7L2 — so your satiety and energy-balance biology shapes an informed conversation with your provider. That is testing before you invest.

Not affiliated: PlexusDx is not affiliated with Noom and has no commercial relationship with the companies discussed in this review.

Related reading on PlexusDx: How To Buy Zepbound, Liraglutide vs Zepbound, Online Zepbound, Oral Zepbound.

Disclaimer: This article is educational. PlexusDx is not affiliated with Noom and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches within the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Want the upstream picture first? Take the Precision Peptide Genetic Test to read your tirzepatide pathway, or explore the Weight Management Protocols to see how PlexusDx pairs the compound with genetic insight.

Frequently Asked Questions about Noom and Zepbound

Is Zepbound the same as Mounjaro?

Both are branded tirzepatide from Eli Lilly, but they carry different labeled indications. Zepbound is positioned for weight management and obstructive sleep apnea, while Mounjaro is labeled for type 2 diabetes. A prescriber selects the appropriate product based on an individual's diagnosis, history and goals rather than the name alone.

Does Noom dispense branded Zepbound or compounded tirzepatide?

That depends on the program's pharmacy partner. A telehealth service may route a prescription to a retail pharmacy for branded Zepbound or to a 503A compounding pharmacy for compounded tirzepatide. Because sourcing affects oversight and cost, verify which route Noom uses on its own website before enrolling.

What might a Zepbound-focused plan cost through Noom?

Noom publishes pricing on its own site, and it shifts over time. Telehealth GLP-1 plans as of April 2026 typically span roughly $200 to $700+ per month depending on the product, subscription tier and dispensing pathway. Because branded products affect totals, confirm the current figure directly with the brand first.

Can the genetic test tell me whether Zepbound will work for me?

No. The Precision Peptide Genetic Test does not predict response to Zepbound or any specific compound. It reads pathway-level variants in FTO, MC4R and TCF7L2 that map your baseline GLP-1 and energy-balance biology — upstream context that applies no matter which program writes the prescription.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.